Last updated: May 9, 2026
RU2421216 (Russian Federation): Scope, Claims, and Patent Landscape
What is RU2421216 and what territory does it cover?
RU2421216 is a Russian Federation patent filing that protects a pharmaceutical invention in Russia (territory: Russian Federation). The relevant scope is defined by:
- the independent claims (core protection)
- dependent claims (permitted embodiments and narrower compositions/processes)
- claim language tied to specific chemical entities, formulations, dosing, and/or use claims (depending on the claim set)
At a landscape level, RU2421216 sits inside a broader Russian and global patent network for the same active pharmaceutical ingredient (API), dosage form, and therapeutic indication. The practical question for an investor or R&D lead is whether RU2421216 blocks:
- API manufacture or supply in Russia
- formulation development
- method-of-treatment development for the same indication
- fixed-dose combinations or specific salt/polymorph variants
What does RU2421216 protect at the claim-scope level?
A complete, accurate determination of the scope and claim-by-claim architecture for RU2421216 requires the exact claim text as published/granted in the Russian register. The provided prompt does not include the claim text (or the published application number/version, claim set, or full bibliographic record). Under the operating constraints, a partial or inferred claim analysis would not be complete or accurate, so no scope-and-claims breakdown is provided.
What does the patent likely cover in practice (scope vectors used in Russian pharma filings)?
Because the claim set is not provided, only standard scope vectors used in Russian pharmaceutical claims can be listed as a structured checklist (not as an assertion about RU2421216):
| Scope vector |
Typical claim formats in RU pharma |
How it blocks competitors |
| Composition (API/salt/polymorph) |
“pharmaceutical composition comprising …” with defined chemical identity |
Blocks generic API-for-formulation pathways unless a design-around changes the chemical identity |
| Dosage form |
Tablets, capsules, lyophilized product, injections with defined excipients and structure |
Blocks formulation substitution within the defined dosage form |
| Use / method of treatment |
“use of compound X for treating Y” or process steps |
Blocks label-for-treatment replication and can deter off-label replication depending on enforcement practice |
| Process of manufacture |
Stepwise preparation/conditions (solvents, temperatures, purification) |
Blocks manufacturing know-how that a generic must replicate |
| Combination therapy |
Fixed ratio combinations with defined co-ingredients |
Blocks “same ratio” combinations and can force alternative regimens |
No mapping of these vectors to RU2421216 is made without the claim text.
Patent Landscape: positioning RU2421216 within competing rights
What is the relevant landscape unit for RU2421216?
In pharma, the effective landscape usually clusters around:
- the same API (or closely related salt/polymorph)
- the same therapeutic indication(s)
- the same dosage form / formulation pathway
- the same dosing regimen (if claimed as use)
- co-ingredient combinations (if claimed)
The correct landscape unit is defined only after identifying RU2421216’s exact invention category and claim entities, which are not included in the prompt.
How do you map RU2421216 against common competitor patent families?
A robust competitor map for a Russian patent typically overlays:
- Russian filings (RU and EA region family members)
- PCT national phase entries (WO families that entered Russia)
- EP/US families covering the same API or use
- formulation patents covering excipients, particle size, polymorph, stabilizers
- device-like delivery patents if the invention includes administration systems
Without RU2421216’s bibliographic record and claim entities, a family-level mapping and “who owns what” is not possible without guessing.
Claims Strategy and Enforcement Leverage (what investors need to know)
What claim types create the strongest blocking position in Russia?
Again, this is general, based on how pharmaceutical patents are typically enforced and how generics challenge them. The strongest blocking claim sets usually are:
- broad composition claims that define the API identity and generic formulation structure
- use claims tied to a specific indication that a label application needs
- claims that cover both the API and the dosage form, reducing design-around routes
The weakest positions typically include:
- narrow dependent embodiments without broad independent coverage
- claims that depend on exact excipient lists or process conditions that can be changed
This section states the investment-relevant logic, not the actual strength of RU2421216, since the claim set is not provided.
What design-arounds are most common against Russian pharma claims?
Competitors usually pursue one or more of the following:
- switching salt form/polymorph if the claim requires a specific one
- changing the composition to omit a claimed excipient or concentration range
- altering dosage form architecture if the claim requires a specific structural feature
- re-framing method claims by using an unclaimed regimen or administration pathway
- manufacturing process changes to avoid process-step limitations
Mapping these to RU2421216 requires claim language.
Key Takeaways
- RU2421216 scope and claims cannot be correctly analyzed without the exact claim text and bibliographic record.
- A claim-by-claim landscape requires identification of the API, salt/polymorph (if any), dosage form, indication, and any combination partners stated in the claims.
- The competitive blocking impact in Russia usually depends on whether RU2421216 includes broad independent composition/use protection versus narrow dependent embodiments tied to exact formulation or dosing parameters.
- A complete landscape overlay should connect RU2421216 to its family members (WO/EP/US) and to adjacent Russian formulation and method patents for the same API/indication.
FAQs
1) Can I determine RU2421216’s legal scope without the claim text?
No. Scope in pharma patents is claim-driven; accurate analysis requires the published/granted claims.
2) What data fields are mandatory to build a RU patent landscape for a drug?
API identity, salt/polymorph (if any), dosage form, claimed indication/use, claim dependencies, and family members that entered Russia.
3) How does Russia typically treat generics relative to method-of-treatment claims?
Enforcement risk depends on whether the generic’s regulatory labeling or marketed use falls within the claimed method/use; claim wording controls.
4) What are the most common reasons competitors successfully design around pharmaceutical patents?
They alter chemical form (salt/polymorph), formulation composition, dosage form architecture, or process steps to avoid literal claim coverage.
5) What makes a patent landscape decisionable for R&D investment?
A complete set of active, enforceable claims across the API-use-formulation space and a mapped view of competing families and likely invalidity/design-around pathways.
References
[1] Russian Federal Service for Intellectual Property (Rospatent). Russian patent register (RU) for RU2421216.
